This application requests continuing support for the Cancer Research Center at the University of Chicago (UCCRC). Clinical and laboratory research is organized into five established programs (Molecular Biology of Cell Growth and Differentiation; Cancer Molecular Genetics; lmmunology and Cancer; Clinical and Experimental Therapeutics, Advanced Imaging) and three developing programs (Breast Cancer, Prostate Cancer, Prevention and Control). Clinical research is a major focus of multidisciplinary activity at the UCCRC. More than 800 patients are enrolled annually on clinical research protocols supported by cooperative agreements to conduct phase I phase II and phase III clinical trials. The UCCRC is the host institution for the Cancer and Leukemia Group B (CALGB) and also participates in the Radiation Therapy Oncology Group, the Gynecologic Oncology Group and the Children's Cancer Group. Funds are requested in this application for Senior Leadership, Program Leaders, Planning and Evaluation, Developmental Funds, Administration, Pilot Trials, the Clinical Protocol Review and Monitoring System and eleven shared resources (Transgenic Mouse/Embryonic Stem Cell Facility; Animal Barrier Facility; DNA Sequencing Facility; Oligopeptide Synthesis Facility; Flow Cytometry and lmmunohistochemistry Facility; Electron Microscopy Facility; NMR Spectroscopy Facility; Monoclonal Antibody Facility; Pharmacology Core Facility; Protocol and Data Management Office and Biostatistics Facility). The overall goals of the UCCRC are (1) to stimulate and support collaborative interdisciplinary laboratory research in cancer; (2) to advance discoveries and new treatment strategies from the laboratory to clinical application; (3) to apply modern techniques of molecular biology, genetics and cytogenetics to the study of human tumors; (4) to conduct multidisciplinary clinical treatment programs for patients with cancer; (5) to provide education and training in cancer research for basic scientists, clinical investigators and health care professionals at all levels of training; (6) to provide access to clinical trials to community oncologists and minority populations via a network of affiliated hospitals and (7) to initiate cancer prevention and control research at the University of Chicago and the Chicago metropolitan area.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014599-25
Application #
2748685
Study Section
Subcommittee G - Education (NCI)
Program Officer
Bhorjee, Jaswant
Project Start
1977-02-01
Project End
2001-07-31
Budget Start
1998-08-01
Budget End
1999-07-31
Support Year
25
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Chicago
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
225410919
City
Chicago
State
IL
Country
United States
Zip Code
60637
Luke, Jason J; Lemons, Jeffrey M; Karrison, Theodore G et al. (2018) Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol 36:1611-1618
Wang, Amy Y; Weiner, Howard; Green, Margaret et al. (2018) A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. J Hematol Oncol 11:4
Sample, Ashley; He, Yu-Ying (2018) Mechanisms and prevention of UV-induced melanoma. Photodermatol Photoimmunol Photomed 34:13-24
Jeong, Choongwon; Witonsky, David B; Basnyat, Buddha et al. (2018) Detecting past and ongoing natural selection among ethnically Tibetan women at high altitude in Nepal. PLoS Genet 14:e1007650
Wang, Xin; Wu, Xingye; Zhang, Zhonglin et al. (2018) Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway. Sci Rep 8:17914
Brown, Hailey M; Biering, Scott B; Zhu, Allen et al. (2018) Demarcation of Viral Shelters Results in Destruction by Membranolytic GTPases: Antiviral Function of Autophagy Proteins and Interferon-Inducible GTPases. Bioessays 40:e1700231
Karrison, Theodore; Kocherginsky, Masha (2018) Restricted mean survival time: Does covariate adjustment improve precision in randomized clinical trials? Clin Trials 15:178-188
An, Ningfei; Khan, Saira; Imgruet, Molly K et al. (2018) Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS. Blood 131:2682-2697
Trujillo, Jonathan A; Sweis, Randy F; Bao, Riyue et al. (2018) T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection. Cancer Immunol Res 6:990-1000
Zeng, Zongyue; Huang, Bo; Huang, Shifeng et al. (2018) The development of a sensitive fluorescent protein-based transcript reporter for high throughput screening of negative modulators of lncRNAs. Genes Dis 5:62-74

Showing the most recent 10 out of 668 publications